Skip to main content
Equibles
RPRX logo

RPRX · Royalty Pharma plc · Metrics

Track RPRX — free

Use RPRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RPRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$63.86 +0.11 (+0.17%) At close · Oct 23
Russell 1000 member Rebalance outlook locked
Market Cap
$36.72B
Shares
575.00M
Volume · Oct 23 4.02M Avg daily vol (3M) 3M

RPRX metrics

91 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$63.86
Market cap
$36.72B

Price action

20 metrics
Price change (1W)
+4.8%
Price change (30D)
+9.4%
Price change (3M)
+8.6%
Price change (6M)
+29.3%
Price change (YTD)
+65.3%
Price change (1Y)
+73.3%
Trailing year
Price change (5Y)
+70.3%
52-week high
$63.96
52-week low
$36.41
Change from 52-week high
-0.2%
Change from 52-week low
+75.4%
Annualized volatility
23.7%
Annualized volatility (3M)
24.6%
Beta
0.3
RSI (14D)
70.4
Price vs SMA 50
+6.9%
Price vs SMA 200
+21.4%
Avg volume (3M)
3.00M
Relative volume
1.3
Average dollar volume
$178.41M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
575.00M

Valuation

12 metrics
P / E (TTM)
34.1
Trailing earnings · reciprocal yield 2.9%
PEG ratio
—
EV / revenue
17.7×
reciprocal yield 5.7%
EV / EBITDA
—
EV / EBIT
29.7×
reciprocal yield 3.4%
P / sales
14.5×
reciprocal yield 6.9%
P / book
3.8
reciprocal yield 26.6%
FCF yield
—
TTM · current market cap
Buyback yield
0.9%
P / FCF
—
P / operating cash flow
12.3
reciprocal yield 8.1%
Earnings yield
2.2%

Historical valuation

8 metrics
P / E historical average (3Y)
25.9×
reciprocal yield 3.9%
P / E historical average (5Y)
46.8×
reciprocal yield 2.1%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
1.4%
Trailing 12 months
Payout ratio
—
Shareholder yield
0.9%
Dividend / share (TTM)
$0.93
Dividend growth YoY
+6.3%
Dividend growth streak
5+
Stored dividend history starts 2020
Last ex-dividend
2026-08-14

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
59.6%
Trailing 12 months
Net margin
32.0%
Gross profit (TTM)
—
Operating profit (TTM)
$1.51B
Net income (TTM)
$812.00M
Trailing 12 months
Diluted EPS (TTM)
$1.87
FCF margin
—
Effective tax rate
0.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$4.55
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$2.71
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$1.45
Operating cash flow per diluted share (TTM)
$5.34
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.43
Stock compensation per diluted share (TTM)
$0.77
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+16.5%
Year over year
Net income growth YoY
-44.4%
Revenue (TTM)
$2.54B
Trailing 12 months
EPS growth YoY
-42.9%
Shares change YoY
-1.0%
Year over year · fewer shares
Revenue CAGR (3Y)
+2.1%
Revenue CAGR (5Y)
+2.3%
EPS CAGR (3Y)
+161.1%
EPS CAGR (5Y)
+6.2%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
8.3%
Return on assets
4.1%
Debt / equity
0.9
Current ratio
2.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.8
Interest coverage
4.2
Net debt / EBITDA
—
Return on invested capital
8.4%
Trailing 12 months
Net cash
−$8.15B
Latest balance sheet
Cash & equivalents
$811.99M
Total assets
$19.82B
Total debt
$8.96B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$2.98B
Capital expenditures (TTM)
—
R&D (TTM)
$238.64M
SG&A (TTM)
—
Stock compensation (TTM)
$427.67M
R&D / revenue
9.4%
Stock compensation / revenue
16.9%

Ownership (13F)

9 metrics
13F filers
653
13F filer change QoQ
+56
Institutional ownership
64.0%
Conviction holders (share of 13F filers)
2.2%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.3%
Holder tenure
16.4
Price vs estimated holder cost
+48.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.8%

Short interest

3 metrics
Short interest
2.2%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$12.97M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1802768 CUSIP G7709Q104 13F (30d) 142 filings 130 filers Visit website Investor relations